Efficacy and safety of selexipag in patients with inoperable or persistent/recurrent CTEPH (SELECT randomised trial)

BACKGROUND: SELECT was the first global randomised controlled trial of selexipag with standard of care in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. METHODS: SELECT was a multicentre, randomised, double-blind, placebo-controlled, parallel-group, group-sequential, phase 3 study (NCT03689244). Adults aged

• Kim, N. H.
• Channick, R.
• Delcroix, M.
• Madani, M.
• Pepke-Zaba, J.
• Borissoff, J. I.
• Easton, V.
• Gesang, S.
• Richard, D.
• Ghofrani, H. A.